Merck

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Merck 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About MRK

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. 

CEO
Robert M. Davis
CEORobert M. Davis
Employees
75,000
Employees75,000
Headquarters
Rahway, New Jersey
HeadquartersRahway, New Jersey
Founded
1891
Founded1891
Employees
75,000
Employees75,000

MRK Key Statistics

Market cap
365.91B
Market cap365.91B
Price-Earnings ratio
118.58
Price-Earnings ratio118.58
Dividend yield
2.26%
Dividend yield2.26%
Average volume
13.80M
Average volume13.80M
High today
$150.00
High today$150.00
Low today
$145.75
Low today$145.75
Open price
$146.27
Open price$146.27
Volume
8.07M
Volume8.07M
52 Week high
$156.92
52 Week high$156.92
52 Week low
$77.58
52 Week low$77.58

Stock Snapshot

Merck(MRK) stock is priced at $148.28, giving the company a market capitalization of 365.91B. It carries a P/E multiple of 118.58 and pays a dividend yield of 2.26%.

During the trading session on 2026-08-29, Merck(MRK) shares reached a daily high of $150.00 and a low of $145.75. At a current price of $148.28, the stock is +1.7% higher than the low and still -1.1% under the high.

Trading activity shows a volume of 8.07M, compared to an average daily volume of 13.8M.

The stock's 52-week range extends from a low of $77.58 to a high of $156.92.

The stock's 52-week range extends from a low of $77.58 to a high of $156.92.

MRK News

TipRanks 7h
Schwab US Dividend Equity ETF Sees Inflows Amid Healthcare Developments

Schwab US Dividend Equity ETF ( $SCHD ) has fallen by 0.88% in the past week. It has experienced a 5-day net inflow of $640.6 million. This is due, in part, to...

Nasdaq 1d
Warren Buffett Thinks Investors Are "Gambling" Right Now. Here are 2 Stocks That Should Be Safe Bets.

Key Points Johnson & Johnson has increased its dividend for 64 consecutive years. Merck has raised its dividend for 26 consecutive years. Both drug companies...

Warren Buffett Thinks Investors Are "Gambling" Right Now. Here are 2 Stocks That Should Be Safe Bets.
Investing.com 1d
Merck stock just backed off all-time highs; should you load up? - Investing.com

...

Merck stock just backed off all-time highs; should you load up? - Investing.com

Analyst ratings

68%

of 31 ratings
Buy
67.7%
Hold
29%
Sell
3.2%

More MRK News

Simply Wall St 2d
Merck Hits A Key Melanoma Milestone, Is The Stock Fully Priced?

Merck (MRK) is back in focus after a Phase 3 study of intismeran autogene with Keytruda met its primary endpoints in melanoma, validating meaningful clinical be...

Merck Hits A Key Melanoma Milestone, Is The Stock Fully Priced?
Simply Wall St 4d
Why Merck Is Up 15.7% After Breakthrough Phase 3 mRNA Melanoma Therapy Data – And What’s Next

On 19 August 2026, Merck & Co. and Moderna reported that their individualized mRNA-based neoantigen therapy intismeran, combined with Keytruda, achieved positiv...

Why Merck Is Up 15.7% After Breakthrough Phase 3 mRNA Melanoma Therapy Data – And What’s Next
24/7 Wall St. 4d
Merck Just Gained 19% in a Month. What Would It Take to Get MRK Stock Up to $200?

Merck Just Gained 19% in a Month. What Would It Take to Get MRK Stock Up to $200? By David Moadel Published Aug 25, 3:51PM EDT Quick Read MRK surged 45% year...

Merck Just Gained 19% in a Month. What Would It Take to Get MRK Stock Up to $200?
TipRanks 4d
Moderna Stock Rises 12.5% Today Following Phase 3 mRNA Cancer Vaccine Win with Merck

Biotech firm Moderna (MRNA) saw its stock rise 12.5% today, building on a multi-day rally after releasing positive Phase 3 trial data for its personalized mRNA...

24/7 Wall St. 4d
Cancer Vaccine Breakthrough Lifts 5 Biotech Names. Here's Who's Best Positioned.

Cancer Vaccine Breakthrough Lifts 5 Biotech Names. Here’s Who’s Best Positioned. By Trey Thoelcke Published Aug 25, 7:15AM EDT Quick Read MRK and MRNA's intis...

Cancer Vaccine Breakthrough Lifts 5 Biotech Names. Here's Who's Best Positioned.
TipRanks 5d
Merck price target raised to $180 from $155 at Wolfe Research

Wolfe Research analyst Alexandria Hammond raised the firm’s price target on Merck (MRK) to $180 from $155 and keeps an Outperform rating on the shares. The firm...

Simply Wall St 5d
Merck Stock May Be 35% Undervalued After Cancer Vaccine Data

Merck stock has delivered a strong 130.2% return over the past 5 years, yet its valuation picture is split, with a Discounted Cash Flow (DCF) estimate pointing...

Merck Stock May Be 35% Undervalued After Cancer Vaccine Data

People also own

Based on the portfolios of people who own MRK. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.